

**БИБЛИОГРАФИЈА (1988 – 2023)
НА АКАД. ДИМИТАР ЕФРЕМОВ**

1. G. Benintende, I. Innocenti ... D. G. Efremov ... [et al.]. *Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study*. **Haematologica**. 2023; 108(11):2240-2243.
2. A. Largeot, V. Klapp ... D.G. Efremov... [et al.]. *Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as therapeutic strategy in CLL*. **Blood**. 2023; 141(26): 3166-3183.
3. F. Fais, D.G. Efremov. Editorial: *The notch signaling pathway in lymphoid malignancies*. **Frontiers in Oncology** [El. resource]. 2023; 13: 1216398.
<https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1216398/full>
4. C. Vitale, V. Griggio ... D.G. Efremov ... [et al.]. *Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia*. **Scientific Reports** [El. resource]. 2023; 13: 16950.
<https://www.nature.com/articles/s41598-023-44039-0>
5. S. Chakraborty ... [et al.], A. J. Dimovski, D. G Efremov. *Rapid Generation of Murine CLL/Richter Syndrome Models By Multiplexed CRISPR/Cas9 Editing of Common CLL Driver Genes*. **Blood**. 2022; 140(suppl. 1):1536-1537.
6. C. Martines ... [et al.], A. Dimovski, D. Efremov. *S135: Crispr/Cas9 Editing Reveals Dependence of Human Richter Syndrome and Murine Cll Cells on Signals From B Cell Receptor, Cxcr4 Receptor and Macrophages but not from Toll-Like Receptors in Vivo*. **HemaSphere**. 2022; 6:36–37.
7. C. Martines ... [et al.], A. J. Dimovski, D. G. Efremov. *Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo*. **Blood**. 2022; 140(22):2335-2347.
8. I. Innocenti, A. Tomasso ... D. G. Efremov ... [et al.]. *Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics*. **Hematological Oncology**. 2022; 40(5):469-474.
9. G. D'Arena, A. Sgambato... D. G. Efremov ... [et al.]. *Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?*. **Hematological Oncology**. 2022; 40(5):835-842.
10. Goral A, Firczuk M, Fidyk K, Sledz M, Simoncello F, Siudakowska K, Pagano G, Moussay E, Paggetti J, Nowakowska P, Gobessi S, Barankiewicz J, Salomon-Perzynski A, Benvenuti F, Efremov DG, Juszczynski P, Lech-Maranda E, Muchowicz A. *A Specific CD44^{lo} CD25^{lo} Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia*. **Front Immunol**. 2022; 13:781364.
11. D'Arena G, Vitale C, Coscia M, Lamorte D, Pietrantuono G, Perutelli F, D'Auria F, Statuto T, Valvano L, Tomasso A, Griggio V, Jones R, Mansueto G, Villani O, D'Agostino S, Viglioglia V, De Feo V, Calapai F, Mannucci C, Sgambato A, Efremov DG, Laurenti L. *CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia*. **Cancers (Basel)**. 2021; 13(16):4239.
12. Chakraborty S, Martines C, Porro F, Fortunati I, Bonato A, Dimishkovska M, Piazza S, Yadav BS, Innocenti I, Fazio R, Vaisitti T, Deaglio S, Zamò A, Dimovski AJ, Laurenti L, Efremov DG. *B Cell Receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter Transformation*. **Blood**. 2021; 138(12):1053-1066.
13. D'Arena G, De Feo V, Pietrantuono G, Seneca E, Mansueto G, Villani O, La Rocca F, D'Auria F, Statuto T, Valvano L, Arruga F, Deaglio S, Efremov DG, Sgambato A, Laurenti L. *CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance*. **Front Oncol**. 2020; 10:584427.
14. Laurenti L, Efremov DG. *Therapeutic Targets in Chronic Lymphocytic Leukemia*. **Cancers (Basel)**. 2020; 12(11):3259.
15. Vervloessem T, Sasi BK, Xerxa E, Karamanou S, Kale J, La Rovere RM, Chakraborty S, Sneyers F, Vogler M, Economou A, Laurenti L, Andrews DW, Efremov DG, Bultynck G. *BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models*. **Cell Death Dis**. 2020; 11(9):769.
16. Corbingi A, Innocenti I, Tomasso A, Pasquale R, Visentin A, Varettoni M, Flospergher E, Autore F, Morelli F, Trentin L, Reda G, Efremov DG, Laurenti L. *Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia*. **Br J Haematol**. 2020; 190(6):901-908.

17. Priebe V, Sartori G, Napoli S, Chung EYL, Cascione L, Kwee I, Arribas AJ, Mensah AA, Rinaldi A, Ponzoni M, Zucca E, Rossi D, Efremov D, Lenz G, Thome M, Bertoni F. *Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.* **Cancers** (Basel). 2020; 12(7):E1912.
18. Efremov DG, Turkalj S, Laurenti L. *Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.* **Cancers** (Basel). 2020; 12(6):E1396.
19. Arruga F, Serra S, Vitale N, Guerra G, Papait A, Gyau BB, Tito F, Efremov D, Vaisitti T, Deaglio S. *Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia.* **Haematologica.** 2020; pii: haematol.2019.242016. doi: 10.3324/haematol.2019.242016. Online ahead of print.
20. Smith LD, Minton AR, Blunt MD, Karydis LI, Dutton DA, Rogers-Broadway KR, Dobson R, Liu R, Norster F, Hogg E, Ashton-Key M, Strefford JC, Jia L, Efremov DG, Helgason GV, Johnson PWM, Stevenson FK, Forconi F, Cragg MS, Tumbarello DA, Packham G, Steele AJ. *BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia.* **Leukemia.** 2020; 34(2):640-644.
21. Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L. *Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.* **Br J Haematol.** 2019; 187(1):e8-e11.
22. Perera S, Allen A, Silva I, Hapugoda M, Wickramarathne MN, Wijesiriwardena I, Allen S, Rees D, Efremov DG, Fisher CA, Weatherall DJ, Premawardhena A. *Genotype-phenotype association analysis identifies the role of α globin genes in modulating disease severity of β thalassaemia intermedia in Sri Lanka.* **Sci Rep.** 2019; 9(1):10116.
23. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. *Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.* **Cancers** (Basel). 2019; 11(7). pii: E896. doi: 10.3390/cancers11070896.
24. Sasi BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzynska B, Stachura J, Zerrouqi A, Bobrowicz M, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, Efremov DG. *Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.* **Leukemia.** 2019; 33(10):2416-2428.
25. Patrussi L, Capitani N, Ulivieri C, Manganaro N, Granai M, Cattaneo F, Kabanova A, Mundo L, Gobessi S, Frezzato F, Visentin A, Finetti F, Pelicci PG, D'Elis MM, Trentin L, Semenzato G, Leoncini L, Efremov DG, Baldari CT. *p66Shc deficiency in the $\epsilon\mu$ -TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.* **Haematologica.** 2019; 104(10):2040-2052.
26. Graczyk-Jarzynka A, Goral A, Muchowicz A, Zagodzón R, Winiarska M, Bajor M, Trzeciecka A, Fidył K, Krupka JA, Cyran J, Szczygiel K, Efremov DG, Gobessi S, Jagielski A, Siudakowska K, Bobrowicz M, Kłopotowska M, Barankiewicz J, Malenda A, Lech-Maranda E, Miazek-Zapala N, Skarzynski PH, Domagala A, Golab J, Firczuk M. *Inhibition of thioredoxin-dependent H₂O₂ removal sensitizes malignant B-cells to pharmacological ascorbate.* **Redox Biol.** 2019; 21:101062.
27. Jakubowska MA, Kerkhofs M, Martines C, Efremov DG, Gerasimenko JV, Gerasimenko OV, Petersen OH, Bultynck G, Vervliet T, Ferdek PE. *ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca²⁺ -signalling dysregulation or toxicity in pancreatic acinar cells.* **Br J Pharmacol.** 2018 Sep 28. doi: 10.1111/bph.14505. [Epub ahead of print]
28. Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G. *Constitutive IP₃ signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP₃ receptor disruptor BIRD-2.* **Cell Death Differ.** 2019; 26(3):531-547.
29. Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, Zagodzón A, Bojarczuk K, Bobrowicz M, Siernicka M, Machnicki MM, Gobessi S, Barankiewicz J, Lech-Maranda E, Efremov DG, Juszczynski P, Calado D, Golab J, Winiarska M. *FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.* **Oncoimmunology.** 2018; 7(5):e1423183.
30. Innocenti I, Autore F, Pasquale R, Morelli F, Efremov DG, Laurenti L. *Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.* **Expert Rev Hematol.** 2017;10(12):1069-1076.

31. Jiménez de Oya N, De Giovanni M, Fioravanti J, Übelhart R, Di Lucia P, Focchi A, Iacovelli S, Efremov DG, Caligaris-Cappio F, Jumaa H, Ghia P, Guidotti LG, Iannacone M. *Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens.* **EMBO Mol Med.** 2017;9(11):1482-1490.
32. Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagodzón A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M. *HDAC6 inhibition up-regulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.* **Blood.** 2017;130(14):1628-1638.
33. Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foa' R. *Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.* **Haematologica.** 2017; 102(9):e352-e355.
34. Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M. *Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.* **Leukemia.** 2017; 31(5):1177-1186.
35. Efremov DG. *IL-4 regulates B-cell receptor signaling in CLL.* **Blood.** 2016; 128:468-469.
36. Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, Efremov DG. *BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.* **Blood.** 2016;127(25):3192-3201.
37. Efremov DG. *FOXO discriminates tonic from chronic in DLBCL.* **Blood.** 2016;127(6):669-70.
38. Engert A, Balduini C, Brand A, et al. *The European Hematology Association Roadmap for European Hematology Research. A Consensus Document.* **Haematologica.** 2016;101(2):115-208.
39. Laurenti L, Innocenti I, Autore F, Sica S, Efremov DG. *New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.* **OncoTargets and Therapy.** 2016;9:421-429
40. Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P, Bellesi S, Efremov DG, Sica S, Mauro FR. *Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.* **Leuk Lymphoma.** 2016;57(10):2429-31.
41. Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, Del Poeta G, Mauro FR, Cortelezzi A, Borza PA, Ghio F, Mondello P, Murru R, Gozzetti A, Cariccio MR, Piccirillo N, Boncompagni R, Cantonetti M, Principe MI, Reda G, Bongarzone V, Cervetti G, Pitini V, Foa' R, Sica S, D'Arena G. *Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.* **Leuk Res.** 2015;39(10):1066-70.
42. Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R. *The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.* **Oncotarget.** 2015;6(22):19102-17.
43. Laurenti L, Autore F, Innocenti I, Vannata B, Piccirillo N, Sorà F, Speziale D, Pompili M, Efremov D, Sica S. *Prevalence, characteristics and management of occult hepatitis B virus infection (OBI) in chronic lymphocytic leukemia patients. A single center experience.* **Leuk Lymphoma.** 2015;56(10):2841-6.
44. Iacovelli S, Hug E, Bennardo S, Duehren-von Minden M, Gobessi S, Rinaldi A, Suljagic M, Bilbao D, Bolasco G, Eckl-Dorna J, Niederberger V, Autore F, Sica S, Laurenti L, Wang H, Cornall RJ, Clarke SH, Croce CM, Bertoni F, Jumaa H, Efremov DG. *Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.* **Blood.** 2015;125(10):1578-1588.
45. Perera PS, Silva I, Hapugoda M, Wickramaratne MN, Wijesiriwardena I, Efremov DG, Fisher CA, Weatherall DJ, Premawardhana A. *Rare Hemoglobin Variants: Hb G-Szuhu (HBB: c.243C>G), Hb G-Coushatta (HBB: c.68A>C) and Hb Mizuho (HBB: c.206T>C) in Sri Lankan Families.* **Hemoglobin.** 2015;39(1):62-5.
46. Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagodzón A, Krol M, Syta A, Podrzywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P,

- Efremov D, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel T, Leusen JHW, Golab J. *Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies*. **MAbs**. 2014;6(5):1300-13.
47. Efremov DG, Gobessi S. *Signal-dependent and signal-independent functions of the B-cell receptor in chronic lymphocytic leukemia*. **Haematologica**. 2014;99(11):1645-6.
48. Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J, Winiarska M. *B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies*. **Leukemia**. 2014;28(5):1163-7.
49. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, Macmurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ. *Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)*. **Blood**. 2014;123(8):1207-13.
50. De Padua L, Laurenti L, Falcucci P, D'arena G, Vannata B, Innocenti I, Autore F, Piccirillo N, Za T, Marietti S, Efremov DG, Sica S. *Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome*. **Ann Hematol**. 2014;93(7):1261-2.
51. Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Piccirillo N, Za T, Bellesi S, Marietti S, Sica S, Efremov DG, Leone G. *Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience*. **Mediterr J Hematol Infect Dis**. 2013; 5(1):e2013031. doi: 10.4084/MJHID.2013.031.
52. Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Sica S, Efremov DG. *The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia*. **Mediterr J Hematol Infect Dis**. 2013; 5(1):e2013027. doi: 10.4084/MJHID.2013.027.
53. Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Brusca A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del-Poeta G, Gaidano G, Gattei V. *Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia*. **Blood**. 2013; 121(24):4902-5.
54. Efremov DG. *Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia*. **Blood**. 2013;121(1):238-9.
55. Efremov DG, Bomben R, Gobessi S, Gattei V. *TLR9 signaling defines distinct prognostic subsets in CLL*. **Front Biosci**. 2013;18:371-86.
56. Chiorazzi N, Efremov DG. *CLL: A tale of one or two signals?* **Cell Res**. 2013;23(2):182-5.
57. Efremov DG, Wiestner A, Laurenti L. *Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL*. **Mediterr J Hematol Infect Dis**. 2012, 4(1): e2012067, DOI 10.4084/MJHID.2012.067
58. Bo MD, Bomben R, Zucchetto A, Poeta GD, Gaidano G, Deaglio S, Efremov DG, Gattei V. *Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy*. **Curr Pharm Des**. 2012; 18(23):3323-34.
59. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, Efremov DG. *Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated chronic lymphocytic leukemia cells by selectively activating the AKT pathway*. **Blood**. 2012; 119(26):6278-87.
60. Bomben R, Gobessi S, Bo MD, Volinia S, Marconi D, Tissino E, Benedetti D, Zucchetto A, Rossi D, Gaidano G, Poeta GD, Laurenti L, Efremov DG, Gattei V. *The miR-17~92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes*. **Leukemia**. 2012; 26(7):1584-93.
61. Careta FP, Gobessi S, Panepucci RA, Bojnik E, de Oliveira FM, Matos DM, Falcao RP, Laurenti L, Zago MA, Efremov DG. *The Aurora A and B kinases are upregulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets*. **Haematologica**. 2012; 97(8):1246-54.
62. Bulian P, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, D'Arena G, Efremov D, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L. *IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia*. **J Transl Med**. 2012; 10:18.
63. Laurenti L, De Padua L, D'Arena G, Vannata B, Innocenti I, Tarnani M, Deaglio S, Sica S, Efremov DG, Leone G. *New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia*. **Mini Rev Med Chem**. 2011; 11:508-18.
64. Efremov DG, Laurenti L. *The Syk kinase as a therapeutic target in leukemia and lymphoma*. **Expert Opin Investig Drugs**. 2011; 20:623-36.

65. Dal-Bo M, Del Giudice I, Bomben R, Capello D, Bertoni F, Forconi F, Laurenti L, Rossi D, Zucchetto A, Pozzato G, Marasca R, Efremov DG, Guarini A, Del Poeta G, Foà R, Gaidano G, Gattei V. *B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage*. **Br J Haematol**. 2011; 153:3-14.
66. Suljagic M, Laurenti L, Tarnani M, Alam M, Malek SN, Efremov DG. *Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B cells*. **Leukemia**. 2010; 24:2063-71.
67. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, Efremov DG. *The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E{micro}-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B cell receptor signaling*. **Blood**. 2010; 116:4894-905.
68. Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov D, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L. *Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia*. **Hematol Oncol**. 2011; 29:91-9.
69. Laurenti L, De Padua L, Tarnani M, Piccirillo N, Falcucci P, D'Arena G, Innocenti I, Marietti S, Efremov DG, Chiusolo P, Zini G, Sora' F, Sica S, Leone G. *Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome*. **Ann Hematol**. 2011; 90:59-65.
70. Efremov DG. *Chic adaptor regulates apoptosis in CLL*. **Blood**. 2010; 115:3647-8.
71. Tarnani M, Laurenti L, Longo PG, Piccirillo N, Gobessi S, Mannocci A, Marietti S, Sica S, Leone G, Efremov DG. *The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia*. **Leuk Res**. 2010; 34:1189-94.
72. Bilous N, Bomben R, Dal Bo M, Capello D, Forconi F, Laurenti L, Bertoni F, Efremov DG, Marasca R, Del Poeta G, Martina Z, Kryachouk I, Dyagil I, Gaidano G, Chumak A, Gattei V, Abramenko I. *Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort*. **Leuk Lymphoma**. 2010; 51:822-38.
73. Tarnani M, D'Arena G, Efremov DG, Marietti S, S S, Leone G, Laurenti L. *The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia*. **Leukemia**. 2010; 24:890-1.
74. Bomben R, Dal-Bo M, Benedetti D, Capello D, Forconi F, Marconi D, Bertoni F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Luciano F, Sozzi E, Cattarossi I, Zucchetto A, Rossi FM, Bulian P, Zucca E, Nicoloso MS, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V. *Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features*. **Clin Cancer Res**. 2010; 16:620-8.
75. Bomben R, Dal Bo M, Capello D, Forconi F, Bertoni F, Maffei R, Laurenti L, Rossi D, Zucca E, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V. *IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia*. **Br J Haematol**. 2010; 149:299-302.
76. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, Deaglio S, Laurenti L, Efremov DG, Gaidano G, Del Poeta G, Gattei V. *Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance*. **J Transl Med**. 2009; 7:76.
77. Carsetti L, Laurenti L, Gobessi S, Longo PG, Leone G, Efremov DG. *Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation*. **Cell Signal**. 2009; 21:1187-94.
78. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, Leone G, Efremov DG. *Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B-cells*. **Leukemia**. 2009; 23:686-97.
79. Toluoso B, De Santis M, Bosello S, Gremese E, Gobessi S, Cuoghi I, Totaro MC, Bigotti G, Rumi C, Efremov DG, Ferraccioli G. *Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype*. **Clin Immunol**. 2009; 131:98-108
80. Bomben R, Dal Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Zucchetto A, Bertoni F, Rossi FM, Bulian P, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan M, Lauria F, Del Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei V. *Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study*. **Br J Haematol**. 2009; 144:492-506
81. Laurenti L, Tarnani M, Innocenti I, Savino G, Battendieri R, Larocca LM, Chiusolo P, Sorà F, Sica S, Efremov D, Leone G. *Chronic Lymphocytic Leukemia With Eyelid Involvement Responding to Alemtuzumab*. **J Clin Oncol**. 2008; 26:5299-301

82. Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, Piccirillo N, Chiusolo P, Sorà F, Innocenti I, Sica S, Leone G. *Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.* **Ann Hematol.** 2008; 87:891-8
83. Longo P, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. *The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.* **Blood.** 2008; 111:846-55.
84. Efremov DG, Gobessi S, Longo PG. *Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.* **Autoimmun Rev.** 2007; 7:102-8.
85. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, Omede P, Scatolini M, Jaksic O, Chiorino G, Efremov D, Malavasi F. *CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.* **Blood.** 2007; 110:4012-21.
86. Laurenti L, Tarnani M, Efremov DG, Chiusolo P, Lai M, De Padua L, Sica S, Leone G. *Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.* **Leukemia.** 2007; 21:1819-21.
87. Panovska-Stavridis I, Cevreska L, Stojanovic A, Efremov D. *Prognostic value of immunoglobulin variable heavy chain gene mutation status: long term follow-up in a series of chronic lymphocytic leukemia patients.* **Prilozi.** 2006; 27:127-37
88. Bomben R, Dal-Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A, Forconi F, Maffei R, Ghia EM, Laurenti L, Bulian P, Del Principe MI, Palermo G, Thorsélius M, Degan M, Campanini R, Guarini A, Del Poeta G, Rosenquist R, Efremov DG, Marasca R, Foà R, Gaidano G, Gattei V. *Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study.* **Blood.** 2007; 109, 2989-98.
89. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. *ZAP-70 enhances B-cell receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B-cells.* **Blood.** 2007; 109:2032-9.
90. Longo P, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, Sica S, Leone G, Efremov DG. *The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.* **Leukemia.** 2007, 21:110-120.
91. Panovska-Stavridis I, Ivanovski M, Siljanovski N, Cevreska L, Efremov DG. *Chronic lymphocytic leukemia patients with a V1-69 gene rearrangement do not have inferior survival with respect to patients that express other unmutated V(H) genes.* **Leuk Res.** 2007, 31:245-248.
92. Laurenti L, Piccioni P, Tarnani M, De Padua L, Garzia M, Efremov DG, Piccirillo N, Chiusolo P, Sica S, Leone G. *Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.* **Leuk Res.** 2007; 31:253-6.
93. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N. *B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.* **Proc Natl Acad Sci U S A.** 2006; 103:11713-8.
94. Capello D, Zucchetto A, Degan M, Bomben R, Dal Bo M, Efremov DG, Laurenti L, Del Poeta G, Gaidano G, Gattei V. *Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL).* **Leuk Res.** 2006; 30:1197-9.
95. Laurenti L, Petlickovski A, Rumi C, Gobessi S, Piccioni P, Tarnani M, Puggioni P, Marrietti S, Sica S, Leone G, Efremov DG. *Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia.* **Haematologica.** 2005; 90:1533-40.
96. Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov DG. *Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B-cells.* **Blood.** 2005; 105:4820-7.
97. Laurenti L, Piccioni P, Tarnani M, Efremov DG, Fiorini A, Garzia M, Sica S. *Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.* **Haematologica.** 2005; 90:1143-5.
98. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, Foa R, Damle RN, Fais F, Messmer D, Rai KR, Ferrarini M, Chiorazzi N. *Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia.* **J. Exp. Med.** 2004; 200, 519-525.

99. Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G. *Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.* **Haematologica.** 2004; 89, 1248-1252.
100. Efremov DG, Georgievski B, Cevreska L, Pivkova A, Panovska I. *Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation.* **Bone Marrow Transplant.** 2003; 31, 515-6.
101. Pavkovic M, Georgievski B, Cevreska L, Spiroski M, Efremov DG. *CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders.* **Am. J. Hematol.** 2003; 72, 147-9.
102. Panovska I, Pavkovic M, Cevreska L, Efremov DG. *Low incidence of bcr-abl transcripts in essential thrombocythemia.* **BJMG.** 2003; 6: 17-21.
103. Benvenuti F, Burrone OR, Efremov DG. *Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for complete tumor protection.* **Gene Ther.** 2000; 7: 605-611.
104. Panovska I, Georgievski B, Stojanovic A, Cevreska L, Efremov DG. *Low Prevalence of Chronic Hepatitis C Virus Infection in B-cell Non-Hodgkin's Lymphoma Patients from a Population with a High Prevalence of Healthy HCV Carriers.* **Br. J. Haematol.** 2000; 109: 249-250.
105. Pozzato G, Burrone O, Baba K, Matsumoto M, Hijiata M, Ota Y, Mazzoran L, Baracetti S, Zorat F, Mishiro S, Efremov DG. *Ethnic difference in the prevalence of monoclonal B-cell proliferations in patients affected by hepatitis C virus chronic liver disease.* **J. Hepatol.** 1999; 30: 990-994.
106. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG. *Somatic hypermutation, clonal diversity and preferential expression of the VH 51p1/VL Humkv325 Ig gene combination in HCV-associated lymphoplasmacytoid lymphoma.* **Blood.** 1998; 91: 2433-2442.
107. Mazzaro C, Efremov DG, Burrone O, Pozzato G. *Hepatitis C virus, mixed cryoglobulinemia and non-Hodgkin's lymphoma.* **Ital. J. Gastroenterol. Hepatol.** 1998; 30: 428-434.
108. Efremov DG, Ivanovski M, Burrone OR. *The Pathologic Significance of the Immunoglobulin Expressed by Chronic Lymphocytic Leukemia B-cells in the Development of Autoimmune Hemolytic Anemia.* **Leuk. Lymphoma.** 1998; 28: 285-293.
109. Efremov DG, Ivanovski M, Pozzato G, Batista FD, Burrone OR. *The leukemic cells of chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce isotype-switched immunoglobulins that are preferentially encoded by the 51p1 and DP-50 VH genes.* **Ann. N. Y. Acad. Sci.** 1997; 815: 443-447.
110. Anand S, Batista FD, Tkach T, Efremov DG, Burrone OR. *Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites.* **Mol. Immunol.** 1997; 34: 175-183.
111. Efremov DG, Ivanovski M, Batista FD, Pozzato G, Burrone OR. *IgM-producing chronic lymphocytic leukemia cells undergo Ig-isotype switching without acquiring somatic mutations.* **J. Clin. Invest.** 1996; 98: 290-298.
112. Efremov DG, Ivanovski M, Siljanovski N, Pozzato G, Cevreska L, Fais F, Chiorazzi N, Batista FD, Burrone OR. *Restricted Immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia.* **Blood.** 1996; 87: 3869-3876.
113. Batista FD, Efremov DG, Burrone OR. *Characterization of a second secreted IgE isoform and identification of an asymmetric pathway of IgE assembly.* **Proc Natl Acad Sci U S A.** 1996; 93: 3399-3404.
114. Batista FD, Anand S, Presani G, Efremov DG, Burrone OR. *The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors.* **J. Exp. Med.** 1996; 184: 2197-2205.
115. Dimovski AJ, Baysal E, Efremov DG, Prior JF, Raven JL, Efremov GD, Huisman THJ. *A large beta-thalassemia deletion in a family of Indonesian-Malay descent.* **Hemoglobin.** 1996; 20: 377-392.
116. Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, Efremov DG, Burrone O, Santini G, Pozzato G. *Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-Interferon therapy.* **Cancer.** 1996; 77: 2604-2613.
117. Batista FD, Efremov DG, Burrone OR. *Characterization and expression of alternatively spliced IgE heavy chain transcripts produced by peripheral blood lymphocytes.* **J. Immunol.** 1995; 154: 209-218.
118. Batista FD, Efremov DG, Tkach T, Burrone OR. *Characterization of the human immunoglobulin epsilon mRNAs and their polyadenylation sites.* **Nucleic Acids Res.** 1995; 23: 4805-4811.
119. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR. *Clonal B-cell expansions in peripheral blood of HCV-infected patients.* **Br. J. Haematol.** 1995; 90: 548.

120. Efremov DG, Dimovski AJ, Huisman TH. *The -158 (C->T) promoter mutation is responsible for the increased transcription of the 3' gamma-globin gene in the Atlanta Type of Hereditary Persistence of Fetal Hemoglobin.* **Blood.** 1994; 83: 3350-3355.
121. Efremov DG, Dimovski AJ, Sukarova E, Schiliro G, Zisovski N, Efremov GD, Burrone OR, Huisman TH. *gamma-mRNA and Hb F levels in beta+ thalassemia.* **Br. J. Haematol.** 1994; 88: 311-317.
122. Efremov DG, Dimovski AJ, Baysal E, Ye Z, Adekile AD, Ribeiro ML, Schiliro G, Altay C, Gurgey A, Efremov GD, Huisman TH. *Possible factors influencing the haemoglobin and foetal haemoglobin levels in patients with beta-thalassemia due to a homozygosity for the IVS-I-6 (T->C) mutation.* **Br. J. Haematol.** 1994; 86: 824-830.
123. Dimovski AJ, Efremov DG, Gu LH, Huisman THJ. *The relative levels of betaA and betaS mRNAs in Hb S heterozygotes and in patients with Hb S-beta+-thalassemia or Hb S-beta+-HPFH combinations.* **Br. J. Haematol.** 1994; 87: 353-356.
124. Efremov DG, Batista FD, Burrone OR. *Molecular analysis of IgE heavy chain transcripts expressed in vivo by peripheral blood lymphocytes from normal and atopic individuals.* **J. Immunol.** 1993; 151: 2195-2207.
125. Dimovski AJ, Efremov DG, Jankovic L, Plaseska D, Juricic D, Efremov GD. *beta-Thalassemia due to a 1605 bp deletion of the 5' beta-globin gene region.* **Br. J. Haematol.** 1993; 85: 143-147.
126. Sikole A, Efremov DG, Dimovski AJ, Efremov GD, Polenakovic M. *Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.* **Nephron.** 1993; 65: 482-484.
127. Efremov DG, Dimovski AJ, Efremov GD. *Detection of beta-thalassemia mutations by ASO hybridization of PCR amplified DNA with digoxigenin ddUTP labeled oligonucleotides.* **Hemoglobin.** 1991; 15: 525-530.
128. Efremov DG, Dimovski AJ, Jankovic L, Efremov GD. *Mutant oligonucleotide extension amplification: A nonlabeling polymerase chain reaction based assay for the detection of point mutations.* **Acta Hematol.** 1991; 85: 66-70.
129. Dimovski A, Efremov DG, Jankovic L, Juricic D, Zisovski N, Stojanovski N, Nikolov N, Petkov GT, Reese AL, Stoming TA, Efremov GD, Huisman THJ. *beta-Thalassemia in Yugoslavia.* **Hemoglobin.** 1990; 14: 15-24.
130. Petkov GH, Efremov GD, Efremov DG, Dimovski A, Tchaicarova P, Tchaicarova R, Rogina B, Agarwal S, Kutlar A, Kutlar F, Reese AL, Stoming TA, Huisman THJ. *beta-Thalassemia in Bulgaria.* **Hemoglobin.** 1990; 14: 25-33.
131. Efremov DG, Efremov GD, Zisovski N, Stojanovski N, Kutlar F, Diaz-Chico JC, Kutlar A, Yang KG, Stoming TA, Huisman THJ. *Variation in clinical severity among patients with Hb Lepore Boston-beta-thalassemia is related to the type of beta-thalassemia.* **Br. J. Haematol.** 1988; 68: 351-355.
132. Diaz-Chico JC, Yang KG, Stoming TA, Efremov DG, Kutlar A, Kutlar F, Aksoy M, Altay C, Gurgey A, Kilinc Y, Huisman THJ. *Mild and severe beta-thalassemia among homozygotes from Turkey: Identification of the types by hybridization of amplified DNA with synthetic probes.* **Blood.** 1988; 71: 248-251.
133. Diaz-Chico JC, Yang KG, Yang KY, Efremov DG, Stoming TA, Huisman THJ. *The detection of beta-globin gene mutations in beta-thalassemia using oligonucleotide probes and amplified DNA.* **Biochim. Biophys. Acta.** 1988; 949: 43-48.
134. Fei YJ, Stoming TA, Efremov GD, Efremov DG, Battacharia R, Gonzalez-Redondo JM, Altay C, Gurgey A, Huisman THJ. *beta-Thalassemia due to a T-A mutation within the ATA box.* **Biochem. Biophys. Res. Commun.** 1988; 153: 741-747.
135. Stoming TA, Diaz-Chico JC, Yang KG, Efremov DG, Huisman THJ. *Newer developments in the identification of beta-thalassemia.* **Hemoglobin.** 1988; 12: 565-576.

Дополнил:
Ациовски Вангел
(Библиотека на МАНУ)
Скопје, Јуни 2024